VBIO Valion Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787740 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-49.6%
TTM net income YoY-16.9%
TTM EPS YoY—
Revenue 3-yr CAGR-35.8%
Net income 3-yr CAGR—
Margins
Gross margin-58.1%
Operating margin-1,210.8%
Net margin-1,557.3%
FCF margin-1,263.5%
EBITDA margin-1,210.4%
Returns
ROE-240.3%
ROA-156.0%
ROIC (approx.)-1,514.1%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-29.7%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $780,000 |
| Cost of revenue | — | $778,000 |
| Gross profit | — | $2,000 |
| R&D expense | $3.13M | $1.31M |
| SG&A expense | $4.77M | $3.16M |
| Operating income | -$7.90M | -$4.48M |
| Interest expense | $146,000 | $0 |
| Pretax income | $8.90M | $5.70M |
| Income tax | $0 | $0 |
| Net income | -$8.88M | -$5.66M |
| EBITDA | -$7.89M | -$4.47M |
| EPS (basic) | -7.84 | -19.68 |
| EPS (diluted) | — | -19.68 |
| Weighted avg. shares (diluted) | — | 287,370 |
| Banking | ||
| Net interest income | — | $6,000 |
| Balance sheet | ||
| Cash & equivalents | $12.64M | $2.00M |
| Receivables | — | $69,000 |
| Inventory | $0 | $319,000 |
| Current assets | $13.01M | $2.64M |
| PP&E, net | $12.64M | $2,000 |
| Goodwill | $3.46M | $0 |
| Intangibles | $2.24M | $0 |
| Total assets | $31.61M | $2.81M |
| Current liabilities | $646,000 | $272,000 |
| Total liabilities | $7.44M | $272,000 |
| Shareholders' equity | $16.80M | $2.54M |
| Shares outstanding | 2.53M | 556,902 |
| Cash flow statement | ||
| Operating cash flow | -$7.00M | -$5.72M |
| Capital expenditure | $38,000 | $0 |
| Free cash flow | -$7.04M | -$5.72M |
| Investing cash flow | -$705,000 | $0 |
| Financing cash flow | $18.35M | $4.33M |
| Depreciation & amortization | $5,000 | $3,000 |
| Stock-based compensation | $564,000 | $229,000 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.